Supported by Scientific Evidence Showing Tissue Repair Quality of Company’s ExosomesTORONTO and HAIFA, Israel, Dec. 12, 2025 ...
Exosomes have become a major focus in modern biomedical research as scientists attempt to understand the underlying causes of illness, identify novel biomarkers, and develop effective therapeutics.
First human dosing of PlexarisTM has occurred in Exopharm’s PLEXOVAL Study PLEXOVAL is a world-first study using a cell free, platelet-derived exosome product manufactured using Exopharm's proprietary ...
SHENZHEN, China, Sept. 16, 2025 /PRNewswire/ -- Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug ...
SUZHOU, China, Sept. 9, 2025 /PRNewswire/ -- ImmVira Group ("ImmVira" or the "Company") recently announced that its lead engineered exosome candidate, MVR-EX105 ("EX105") is featured in a poster ...
Advancing Exosome Technology to Address Inflammatory Conditions in Women's Health SEOUL, EUNPYEONG, SOUTH KOREA, July 9, 2025 /EINPresswire.com/ -- ILIAS Biologics ...
Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the ...
The certification covers two proprietary ingredients derived from Sparkling Sciences' advanced biotechnology, which integrates clinical-grade purification with freeze-drying processes: Human Hair ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback